Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
|Videos|May 11, 2021
Mood Disorders: A Family Illness
Author(s)Susan J. Noonan, MD, MPH
Mood disorders can be genetic and deeply affect surrounding people...
Advertisement
Susan J. Noonan, MD, MPH, discusses how important it is to see a patient in their social setting, specifically their family.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
5